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Background: Unresolved medication discrepancies during hospitalization can contribute to adverse drug events,
resulting in patient harm. Discrepancies can be reduced by performing medication reconciliation; however, effective
implementation of medication reconciliation has proven to be challenging. The goals of the Multi-Center
Medication Reconciliation Quality Improvement Study (MARQUIS) are to operationalize best practices for inpatient
medication reconciliation, test their effect on potentially harmful unintentional medication discrepancies,
and understand barriers and facilitators of successful implementation.
Methods: Six U.S. hospitals are participating in this quality improvement mentored implementation study. Each
hospital has collected baseline data on the primary outcome: the number of potentially harmful unintentional
medication discrepancies per patient, as determined by a trained on-site pharmacist taking a “gold standard”
medication history. With the guidance of their mentors, each site has also begun to implement one or more of 11
best practices to improve medication reconciliation. To understand the effect of the implemented interventions on
hospital staff and culture, we are performing mixed methods program evaluation including surveys, interviews,
and focus groups of front line staff and hospital leaders.
Discussion: At baseline the number of unintentional medication discrepancies in admission and discharge orders
per patient varies by site from 2.35 to 4.67 (mean=3.35). Most discrepancies are due to history errors (mean 2.12 per
patient) as opposed to reconciliation errors (mean 1.23 per patient). Potentially harmful medication discrepancies
averages 0.45 per patient and varies by site from 0.13 to 0.82 per patient. We discuss several barriers to
implementation encountered thus far. In the end, we anticipate that MARQUIS tools and lessons learned have the
potential to decrease medication discrepancies and improve patient outcomes.
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One of the most prevalent hazards facing hospitalized
patients is unintentional medication discrepancies, i.e.
unexplained differences in documented medication regi-
mens across different sites of care [1,2]. Unresolved
medication discrepancies can contribute to adverse drug
events (ADEs), resulting in patient harm [3,4]. Nearly
two-thirds of inpatients have at least one unexplained
discrepancy in their admission medication history, and
some studies found up to 3 medication discrepancies per
patient [5-7]. Such medication discrepancies are either
caused by history errors (i.e., errors in determining a pa-
tient’s preadmission medication list) or reconciliation er-
rors (i.e., errors in orders despite accurate medication
histories) [3,4].
One way to minimize medication discrepancies and
improve patient safety is to perform high quality medica-
tion reconciliation, defined as the process of identifying
the most accurate list of all medications a patient is tak-
ing and using this list to provide correct medications for
patients anywhere within the healthcare system [8,9].
Since 2005 The Joint Commission (TJC) has required
U.S. hospitals to conduct medication reconciliation on ad-
mission, upon transfer, and at discharge [10]. Addition-
ally, the World Health Organization has encouraged all
member states to implement medication reconciliation
at care transitions [11]. When tested, hospital-based
medication reconciliation interventions have consistently
demonstrated reductions in medication discrepancies,
though effects on more distal outcomes such as readmis-
sion have been less consistent and limited by study size
[12,13]. Yet, one study at two large urban academic hos-
pitals found that general medical inpatients averaged
more than one potentially harmful discrepancy in either
admission or discharge medication orders despite docu-
mented completion of medication reconciliation [14].
Though medication reconciliation practices are re-
quired at care transitions throughout hospitalization, im-
plementation has been challenging for many hospitals
because it often involves a dramatic change in work pro-
cesses and additional tasks for busy clinicians. Further-
more, the implementation of medication reconciliation
interventions varies widely across hospitals, and hospi-
tals need clearer guidance on which interventions are
more likely to be successful in their local environment
[15]. Moreover, it has been relatively easy for hospitals
to document compliance with medication reconciliation
processes to meet national and international standards
without demonstrating that medication safety has actu-
ally improved. To identify and address the barriers to
implementing medication reconciliation, an Agency for
Healthcare Research and Quality (AHRQ)-funded con-
ference organized by the Society of Hospital Medicine
(SHM) in 2009 brought together 36 key stakeholdersfrom 20 organizations representing healthcare policy, pa-
tient safety, regulatory, technology, and consumer and
medical professional groups. The conference yielded a
White Paper with recommendations, including a call for
further research [16]. To address the latter, SHM
subsequently received funding from AHRQ to conduct
the Multi-Center Medication Reconciliation Quality
Improvement Study (MARQUIS; clinicaltrials.gov iden-
tifier NCT01337063).
The specific aims of MARQUIS are to:
1. Develop a toolkit consolidating the best practices for
medication reconciliation, based on the strongest
evidence available.
2. Conduct a multi-site mentored quality improvement
(QI) study in which each site adapts the tools for its
own environment and implements them.
3. Assess the effects of medication reconciliation QI
interventions on unintentional medication
discrepancies with potential for patient harm.
4. Conduct rigorous program evaluation to determine
the most important components of a medication
reconciliation program and how best to implement
them.
This paper describes the design and early methodo-
logical lessons learned from MARQUIS, an example of
real-world, rigorous, mixed methods QI research. It is
our hope that the design of the study, rationale for that
design, and early experiences will be useful for other
medication safety efforts, as well as for QI and patient
safety research in general.
Methods
Conceptual framework
The MARQUIS conceptual framework is based on
Brown and Lilford’s model for evaluating patient safety
interventions, which is an adaptation of Donabedian’s
“structure—process—outcome” model [17-21]. The model
distinguishes interventions that focus on management
processes (e.g., provider training) from those that focus on
clinical processes (e.g., tools supporting medication list
comparisons across care transitions). MARQUIS involves
both types of interventions, focusing primarily on the lat-
ter. To better understand why interventions succeed or
fail, we assess contextual factors (i.e., micro- and macro-
organizational structure and existing management pro-
cesses) and intervening variables (e.g., team climate, safety
culture, and knowledge of medication safety principles,
Figure 1). Also important to understanding whether inter-
ventions succeed or fail is intervention fidelity, or the
faithfulness with which the intervention is performed,
which can be influenced by how usable the tools are and
the degree of training and support given to front-line
Structure:
Micro- and
Macro-
organizational
structure
Management 
Processes: 
Number and types of 
clinical personnel 
involved in medication 
reconciliation; resources 
provided; training of new 
staff
Intervening 
variables: 
Knowledge, 
attitudes and 
beliefs re: 
medication safety
Clinical
Processes:
Medication
Reconciliation
process
measures
Fidelity: As
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Direct
Observation by 
site mentors 
Patient
outcomes:
Unintentional
medication
discrepancies,
patient
satisfaction,
healthcare
utilization 
Specific Intervention: Assessed by 
Medication Reconciliation intervention 
score. Influenced by training and technical 
support for intervention; usability of tools 
Figure 1 Conceptual framework for MARQUIS.
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Figure 1). These are measured as an “intervention score”
updated monthly to assess what toolkit components have
been adopted and how the state of medication reconcili-
ation changes over time (Table 1). Along with the
MARQUIS intervention itself, each of the contextual fac-
tors may affect the patient-level outcomes being assessed,
such as unintentional medication discrepancies, patient
satisfaction, and healthcare utilization (i.e., items to the
right of the intervention, Figure 1).Toolkit
The MARQUIS toolkit, described elsewhere, [22] syn-
thesizes best practices in medication reconciliation and
provides aids to facilitate their implementation. The
toolkit components were informed by a systematic re-
view of medication reconciliation interventions, [12] the
AHRQ-funded conference of stakeholders,[16] and the
work of the MARQUIS investigators and advisory board.
Each toolkit component is framed as a standardized
functional goal (e.g., “Improve access to preadmission
medication sources”). This approach is ideal for complex
QI interventions, [23] allowing sites to: 1) integrate
intervention components with their baseline medication
reconciliation efforts, information system capabilities,
and organizational structures; and 2) add, customize,
and iteratively refine the toolkit components and their
implementation over time. This approach also improves
generalizability, allowing other organizations to applythe lessons learned regardless of their culture or unique
circumstances.
While recognizing the importance of flexibility, it was
nevertheless important to have some common elements
across sites. Thus, each site prioritized the implementation
of certain toolkit components based on their potential for
improvement and effort required. These included provider
education on medication history taking, patient education
and teach-back at discharge, patient risk stratification, and
more intensive medication reconciliation efforts in high-
risk patients.
Study sites
Six U.S. sites are participating in this study: 3 academic
medical centers, 2 community hospitals, and 1 Veterans
Affairs hospital. We purposely chose sites that vary in
size, academic affiliation, geographic location, and use of
health information technology (Table 2). However, all
sites had several common features: 1) medication recon-
ciliation was a priority; 2) hospital leadership was com-
mitted to making further improvements in the process;
3) an active hospitalist group was engaged in QI; 4) a
suitable hospitalist and/or pharmacist clinical champion
at each site; and 5) each site planned to use primarily its
own resources to pursue this effort.
Patient subjects are drawn from the medical and surgical
inpatient, non-critical care units of each site, and are in-
cluded if hospitalized long enough for a “gold-standard”
medication history to be obtained by a study pharmacist
(i.e., generally more than 24 hours). Institutional Review
Table 1 Intervention components and scoring system
Toolkit component Standardization by function Scoring system for analysis
Definition of Medication
Reconciliation
Definition exists, is widely disseminated and can be
articulated by staff involved in the medication
reconciliation process
0-24 points in 8-point increments, depending on
whether definition exists, is widely implemented, and
can be articulated by >80% of staff involved in the
medication reconciliation process
Assigning roles and responsibilities
to clinical personnel
Roles and responsibilities are well defined for each
phase of medication reconciliation and can be
articulated by staff involved in the medication
reconciliation process; process owner (e.g., attending
physician) is well defined and known by those who
own the process
0-12 points in 4-point increments, depending on
whether roles are well defined, defined for each phase
of the medication reconciliation process, and can be
articulated by >80% of staff
0–12 points in 4 point increments, depending on
whether process owner is well defined and what
proportion of staff in that role can articulate that they
in fact own the process
Improving access to preadmission
medication sources
All sites improve exchange of medication information
across settings, e.g., community pharmacy prescription
information, outpatient medication lists, and inpatient
discharge medication orders to all clinical settings
0-24 points in 6 point increments for electronic access
to outpatient pharmacy information, access to
outpatient medications, access to discharge medication
orders from prior hospitalizations, and access to patient
personal health records.
(can get up to 12 points if have facilitated paper access
to these sources)
Encouraging patient-owned
medication lists
All sites develop (on paper or 0-24 points in 6 point increments, depending on
whether a standard medication form exists, to what
extent patients use it, whether a system is in place to
keep it updated, and whether the form is universally
accessible
electronically) a universal instrument to capture the
current medication list, based on steering committee
guidelines
Educating providers on how to
take a best possible medication
history
Providers receive training in taking a best possible
medication history, receive feedback on their skills,
and have time to perform it well
0-12 points in 4 point increments, depending on
whether clinicians are trained to take a medication
history, whether time is available to take an adequate
history in >80% of patients, and what portion of the
staff have ever received feedback in their history taking
Implementing discharge
counseling that includes patient
education and teach back
Providers counsel patients regarding discharge
medications using a standard script that
accommodates patients with low health literacy
0-12 points in 4 point increments, depending on
whether a standard script is available for discharge
counseling, whether health literacy tools are used, and
whether >80% of staff is trained in discharge
counseling, including patient centered communication
Identifying patients as high vs.
low-intermediate risk by
stratification
Sites use established risk factors to identify patients at
high risk for medication errors, and patient risk drives
the type of intervention received
0-24 points available by calculating the product of the
two below areas:
0–4 points available depending on whether there is a
standard tool available to identify high risk patients
and is used in >80% of patients
0–6 points available depending on whether the tool
drives the intervention intensity, and >80% of eligible
patients receive the high-intensity intervention
Implementing intense vs. standard
bundle
High-risk patients receive a high-intensity medication
reconciliation bundle by providers who are trained
and have time to carry it out
0-24 points in 6 point increments depending on
whether definition exists for standard and intense
intervention, is embraced widely, staff are well trained,
and are given adequate time to carry out the intensive
bundle in high-risk patients
Implementing and improving
electronic medication
reconciliation applications where
possible
Where possible, take advantage of electronic health
record infrastructure and electronic medication
reconciliation products to facilitate bidirectional
transfer of medication information across settings,
compare regimens across settings, and electronically
document the reconciliation process
26 maximum points available based on electronic
medication reconciliation tools having the following
features: ability to compare various sources of
preadmission medication information, access to
medication adherence information, ability to document
and verify a medication history, facilitation and
verification of admission and discharge medication
reconciliation, facilitation of admission and discharge
order-writing, facilitation of patient/caregiver education,
tools to facilitate communication with post-discharge
providers, features to improve the reliability of the
medication reconciliation process, and tools to identify
high risk patients
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Table 1 Intervention components and scoring system (Continued)
Implementing components using
phased approach
Sites implement medication reconciliation
improvements in a phased manor using best practices
for continuous quality improvement
0-24 points in 6 point increments, depending on
whether a plan exists to modify the intervention over
time, to expand the intervention beyond the initial
pilot sites, whether a time frame for expansion has
been established and if the QI team has all the right
personnel
Utilizing social marketing and
engaging community resources
Sites identify, cultivate, and improve relationships with
community resources such as local or regional QI
organizations, dominant local pharmacies and payors,
and local public health agencies with a goal of
working together to improve patient education,
transfer of information, and aligning financial
incentives
0-24 points in 3 point increments, depending on usage
of community resources and a patient safety advisory
board in medication reconciliation, and usage of social
marketing techniques with patients and providers
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Healthcare System. In addition, each study site’s IRB
reviewed the study: four considered it an exempt QI pro-
ject, while two sites required informed consent of patients
prior to participation. Informed consent has been incorpo-
rated into the data collection process at these sites.
Mentored local implementation
MARQUIS utilizes SHM’s mentored implementation ap-
proach [24], providing each site with a hospitalist men-
tor to facilitate toolkit implementation. Each mentor has
QI expertise and performs distance mentoring throughTable 2 Baseline characteristics of participating sites
Site 1 2 3
Hospital Type AMC1 /
Community
Community Com
Region Northeast Southeast Sout
Setting Urban Suburban Subu
Number of Beds 653 110 535
Teaching Status Teaching Teaching Non
Inpatient CPOE3 Yes (Cerner) No (moving to
Cerner)
No
Medication Reconciliation
Software
Yes, integrated
with CPOE
No (but yes with
Cerner)
Yes
% patients for whom site
has electronic access to
ambulatory medication
history
50% 0% <10%
Clinicians primarily
responsible for taking
medication histories
Jointly shared by
physicians and
nurses
Nurses first, then
physicians
Phar
nurs
Process of medication
reconciliation at discharge
Physicians use
electronic tool to
reconcile
medications
Nurses fill out a
reconciliation form,
physicians reconcile
medications
Phys
reco
med
usin
form
1 Academic medical center.
2 Veterans Affairs medical center.
3 Computerized physician order entry.
4 Nurse practitioners/Physician assistants.monthly calls with the study site’s mentee/clinical cham-
pion, based upon the MARQUIS Implementation Guide
which explains how to use the toolkit [25]. Each study
site also receives two visits from the mentor, important
from a QI standpoint (e.g., to maintain institutional sup-
port and enthusiasm among the local QI team, and better
understand local practices) and from a research standpoint
(e.g., to assess intervention fidelity and other barriers and
facilitators of implementation). Additionally, SHM pro-
vides sites with an assigned lead project manager and re-
search assistants located at SHM headquarters to assist
with monitoring progress and collecting and analyzing4 5 6
munity AMC AMC VAMC2
heast Midwest West Coast Midwest
rban Urban Urban Rural
600 450 45
-teaching Teaching Teaching Teaching
Yes (Epic) No (moving to Epic) Yes
Yes,
integrated
with CPOE
In progress (yes with
Epic/Apex)
Yes, not fully
integrated
~100% 50% 95%
macy and
ing
Nurses Physicians Residents and
PAs
icians
ncile
ications
g paper
Physicians/
NPs/
Physicians write orders,
pharmacists available by
request to reconcile
medications
Physicians or
pharmacists,
depending on
time of dayPAs
4
reconcile
discharge
medications
Salanitro et al. BMC Health Services Research 2013, 13:230 Page 6 of 12
http://www.biomedcentral.com/1472-6963/13/230data. Through the mentored implementation infrastruc-
ture, MARQUIS is affordable, adaptable, generalizable,
scalable, and feasible for wide dissemination.
At each study site, a local QI team, led by the mentee/
clinical champion conducts monthly meetings to oversee
intervention implementation and data collection, as well
as to address protocol questions and determine the ef-
fectiveness of the interventions. Sites can access a cen-
tral website with additional resources and a listserv. The
monthly conference calls with their mentor and ad lib
email communications promote a consistent approach
across sites [16].Outcome assessment
Study outcomes are assessed from 6 months pre-
intervention through 21 months post-intervention
(Table 3). The primary outcome is the number of poten-
tially harmful unintentional medication discrepancies
per patient, determined by a trained on-site pharmacist
taking a “gold standard” medication history on a ran-
dom sample of patients (20–25 per month). This history
is then compared to the primary team’s medication his-
tory and to admission and discharge orders. For dis-
crepancies in admission or discharge orders not caused
by history errors, the pharmacist reviews the medical
record for a clinical explanation, and if necessary, talks
with the medical team. This allows sites to distinguish
unintentional medication discrepancies (i.e., due to recon-
ciliation errors) from intentional medication changes.
Physician adjudicators, blinded to the status of interven-
tion implementation, record and categorize unintentional
medication discrepancies with respect to: 1) timing
(admission vs. discharge); 2) type (omission, additional medi-
cation, change in dose, route, frequency, or formulation, orTable 3 Primary and secondary patient outcomes
Outcome Descr
Primary outcome
Unintentional Medication Discrepancies in admission and discharge
orders with potential for patient harm
Numb
Process measures
Accuracy of preadmission medication history Propo
patien
Absence of discharge reconciliation errors Propo
reconc
Preadmission medication history documented within 24 hours of
admission
Propo
docum
Other outcome measures
Emergency Department visit or readmission to index hospital within
30 days of discharge
Propo
Patient Satisfaction on HCAHPS1 survey Globa
“usual
1 Hospital Consumer Assessment of Healthcare Providers and Systems.other); 3) reason (history vs. reconciliation error); 4) po-
tential for harm; and, 5) potential severity.
Secondary outcomes include accuracy and timeliness of
the medical team’s documented admission medication his-
tory, absence of discharge reconciliation errors, unplanned
healthcare utilization (i.e., readmission or emergency
department use), and patient satisfaction. Unplanned
healthcare utilization to the same site within 30 days of
discharge is determined from hospital records on all eli-
gible patients. We examine patient satisfaction scores on
the global satisfaction and the medication specific di-
mensions from the Hospital Consumer Assessment of
Healthcare Providers and Systems (HCAHPS) survey, and
will be aggregated by service, unit, and time period as data
are available.
Contextual factors are measured using surveys of pro-
viders directly involved in the medication reconciliation
process. Additionally, we measure intervention fidelity
using direct observation during site visits, and evaluate
training, support, and other steps offered to improve fi-
delity. Importantly, the extent of implementation is
quantified as an intervention “score” for each toolkit
component (Table 1) and factored into the analysis. The
score is completed by the clinical champion at each site,
informed by surveys administered to front-line clinicians
who are directly involved in the medication reconcili-
ation process when necessary.
Data quality assurance
In an effort to ensure consistency of on-site pharmacist
data collection, the research team: 1) conducts monthly
phone meetings with on-site pharmacists in which a pa-
tient case is reviewed for consistency and all discrepan-
cies discussed; 2) provides on-site pharmacists with an
updated ‘frequently asked questions’ (FAQ) documentiption
er of discrepancies per patient with potential for harm
rtion with accurate medication histories; number of history errors per
t with potential for harm
rtion with error-free discharge medication orders; number of discharge
iliation errors per patient
rtion of cases with on-time preadmission medication history
entation
rtion of patients with ED visit or readmission
l satisfaction score; medication specific score; proportion who responded
ly or always” to medication questions
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with the research team’s pharmacist to observe data col-
lection processes and provide feedback, including how
to improve process efficiency.
To ensure the consistency of the adjudication process,
the principal investigator (PI) conducts a quarterly confer-
ence call with the sites’ physician adjudicators to discuss
cases. In addition, the PI and a co-investigator review 6
cases from each site quarterly and review the results indi-
vidually with each site’s adjudicators. A FAQ document
for adjudicators is updated and redistributed as needed.
Web-based data center
The study sites utilize a web-based data collection and
reporting system built specifically for this study. The sys-
tem creates HIPAA-compliant de-identified data sets for
the coordinating data center and all investigators. The
system allows for identification, classification, and adju-
dication of all discrepancies. Unintentional discrepancies
identified by the on-site pharmacist are flagged in the
system for physician adjudication. The data center pro-
vides detailed reports to trend discrepancies, facilitates
uploads of patient-specific administrative data, tracks
implementation of intervention components, and pro-
vides tools to support mentored implementation. It also
provides tracking for patient enrollment compared to
monthly targets.
Statistical analysis
The primary outcome will be analyzed using multivari-
able Poisson regression, including random effects and
clustering of patients by site and treating physician. To
account for temporal trends and the varied introduction
of interventions by site, we will employ an interrupted
time series analysis on all 3,600 patients across the 6
sites, evaluating outcomes monthly for 6 months pre-
intervention and 21 months post-implementation [26].
The outcome is assessed as both a change from site-
specific baseline temporal trends (i.e., change in slope)
and sudden improvement with implementation of the
intervention components (i.e., change in y-intercept). If
each site has concurrent controls, these can be entered
into the model to partially adjust for the effect of con-
current interventions. The model also allows for the de-
tection of iterative refinement of the intervention (i.e.,
continuous improvement over time), as well as ceiling
effects (i.e., lack of continued improvement beyond a
certain threshold).
We will assess implementation of each component of
the toolkit monthly, using the scoring system on a scale
of no adoption to complete adoption for each compo-
nent (Table 1). Because many of the sites have already
implemented pieces of the interventions, their scores
often do not start at zero, and scores increase with theimplementation of interventions to a maximum score of
318. The scores for each component will be entered into
the multivariable model as time-varying covariates, such
that we can determine whether implementation of a par-
ticular component is correlated with improved outcomes
thereafter. This allows us to make inferences about the
most important components of the intervention.
Power and sample size
For a stable estimate of temporal trends, each site’s data
collection goal is approximately 22 patients per month,
beginning 6 months pre-intervention through 21 months
post-intervention. Due to our study design it is impos-
sible to know a priori the nature of our post-
intervention data, and therefore what our actual power
would be to look at the effect of any specific interven-
tion. However, based on prior research, we assumed that
the number of medication discrepancies would follow a
Poisson distribution and that, in the absence of an inter-
vention, each hospitalized patient would have an average
of 1.5 potentially harmful medication discrepancies in
admission and discharge orders combined [27]. We also
conservatively assumed that an intervention would be
implemented at only 1 of 6 sites with 12, not 21, months
of follow-up due to delays in planning and phasing in
the intervention widely. This would yield data from 133
patients pre-intervention and 266 patients post-
intervention. With these estimates and alpha = 0.05, we
would have 90% power to detect a reduction in the
mean number of medication discrepancies from 1.5 per
patient to 1.1 per patient [27].
As sites began to implement the intervention, one
methodological issue that arose was the extent to which
sites should over-sample data from hospital areas receiv-
ing early versions of the intervention. We decided on a
3:1 ratio of intervention to control patients during the
intervention period. This allows for concurrent controls
during the spread of the intervention, while maintaining
an adequate sample of intervention patients to evaluate
effects on patients outcomes.
Program evaluation
We will evaluate the influence of contextual factors,
intervention fidelity, and intervening variables on imple-
mentation and outcomes using a mixed methods ap-
proach (Table 4). Measures of context are gathered
using front-line staff and site surveys, direct observation,
focus groups and interviews. At baseline, each site com-
pleted a site leader survey and front-line staff surveys to
provide a semi-quantitative measurement of these issues.
After the start of intervention implementation, a qualita-
tive researcher conducts on-site focus groups with front-
line staff and the QI team and interviews hospital
leadership. At 12 months post-intervention, follow-up
Table 4 Program evaluation
Outcome Timing Data sources Time required Data collection
process
Form of analytic
variable
Intervention assessment
Medication Reconciliation
Intervention Score
Monthly throughout
the intervention
Surveys to site leaders at each
site, confirmed by mentor
1 hour for baseline
assessment,
15–20 minutes for
subsequent
assessments
Survey completed
in QuesGen
0-24 scale for each
facet of medication
reconciliation; total
score
Front-line staff Surveys to
inform medication
reconciliation intervention
score
As needed
throughout the study
period as
interventions
implemented likely to
affect results
Surveys completed by
stakeholders (separate survey
for outpatient clinicians)
10 minutes per
survey
Survey
administered to all
potential
stakeholders using
on-line survey
software
Results used
descriptively and to
inform Medication
Reconciliation
intervention score
Measures of context
Macro- and Micro-
organizational structure
Prior to intervention Modification of RAND ICICE
organizational survey [29]
completed by site leaders with
help from administrative/
financial personnel
1 hour per site Survey emailed to
respondents
Varies by question
type
Safety culture, work climate,
and teamwork
Prior to intervention Modification of AHRQ patient
safety culture survey [30]
completed by stakeholders (e.
g., pharmacists, nurses,
physicians)
10 minutes per
survey
Survey
administered to all
potential
stakeholders using
on-line survey
software
Composite
frequency of
positive responses
in each of 10
dimensions of
safety
Satisfaction with medication
reconciliation process and
software, perceptions of
errors related to medication
reconciliation
Prior to intervention,
again post-
intervention
Survey completed by
stakeholders
5 minutes per
survey
As with safety
culture
Frequency of
positive responses
Job satisfaction and burnout Prior to intervention,
again post-
intervention
Surveys [31,32] 5 minutes per
survey
As with safety
culture
Frequency of
positive responses
Qualitative information
Focus Groups At first site visit 5 focus groups of 6–8
representative stakeholders
each, grouped by type, 35
total per site
60-90 minutes Administered by
qualitative
researcher
Individual Interviews Follow-up phone calls
one year after focus
groups
One-on-one interviews with
champions and 2–3 key
opinion leaders per site
30-45 minutes Administered by
phone by
qualitative
researcher
Intervention fidelity
Intervention Fidelity At each site visit Direct observation of
medication reconciliation
process
6 hours at each
visit (over two
days)
Mentor Mean percent
completion of each
process component;
process fidelity
scale (1–4)
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groups and interviews, a convenience sample of staff is
selected by role and department to ensure broad repre-
sentation [28].
Intervention fidelity is assessed by direct, semi-
structured observation of the site’s medication recon-
ciliation process by their mentor during site visits at 3
and 12 months after implementation of the intervention.The observation protocol evaluates five steps of the
medication reconciliation process: taking an admission
medication history, identifying high risk patients to re-
ceive a high intensity medication reconciliation interven-
tion, performing discharge medication reconciliation,
performing discharge medication counseling using the
teach back method, and forwarding the discharge medi-
cation list to the next provider of care after discharge.
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the intervention is being implemented as designed (con-
tent fidelity) and rates how well it was performed on a 1
to 4 scale (process fidelity) [33]. The observation forms
also allow documentation of systems issues that impact
the medication reconciliation process based on the
Systems Engineering Initiative for Patient Safety (SEIPS)
model’s [34] 5 domains: people, technology/tools, tasks,
organization, and environment. Mentors received group
training on how to assess fidelity, using a coding manual
with standardized examples and training from a human
factors expert. Mentors share feedback about the direct
observations during the site visit with the site leader
and QI team.
Intervening variables (i.e., in determining intervention
fidelity) are assessed from surveys of front-line staff pre-
and post-intervention. Topics include the quality of edu-
cation and training received in the intervention (e.g., in
taking medication histories), degree of input into inter-
vention design, and adequacy of staffing and time to
complete medication reconciliation processes. Other
barriers and facilitators of intervention implementation
are determined from structured and open-ended ques-
tions regarding the front-line staff ’s opinions of the
medication reconciliation process and its perceived im-
pact on patient care.Figure 2 MARQUIS study timeline.Study timeline
Figure 2 outlines the timeline of the study. The study’s
three critical time points are: intervention start, interim
evaluation with iterative refinement of the interven-
tion and a second draft of the implementation guide
9 months after the start, and end of the intervention
after 21 months.
Discussion
Baseline data collection began March 2011 and was
completed August 2012. Over 1,000 patients have been
enrolled to date across the 6 sites, of which 980 have
data entered in a centralized database (Table 5). Of
these, preliminary analyses show 844 patients have had
discrepancies adjudicated for potential harm. The total
number of unintentional medication discrepancies in ad-
mission and discharge orders per patient varies by site
from 2.35 to 4.67 (mean = 3.35). Consistent with prior
research, most discrepancies are due to history errors
(mean 2.12 per patient) as opposed to reconciliation er-
rors (mean 1.23 per patient) [14]. The number of poten-
tially harmful medication discrepancies averages 0.45 per
patient and varies by site from 0.13 to 0.82 per patient.
In comparison, in prior studies by Schnipper et al. po-
tentially harmful medication discrepancies began at 1.44
per patient, then decreased to 1.05 and then 0.32 per
Table 5 Baseline results
All sites A B C D E F
(N=927) (n=313) (n=360) (n=124) (n=150) (n=82) (n=22)
Total discrepancies per patient (history and reconciliation): admission and
discharge
3.77 4.52 2.43 2.91 3.27 3.16 1.73
Total discrepancies at admission 1.72 2.16 1.11 1.02 1.49 1.35 0.73
Total discrepancies at discharge 2.05 2.36 1.33 1.89 1.79 1.80 1.00
History discrepancies: admission and discharge 2.39 3.36 1.98 1.91 0.66 0.87 2.59
History discrepancies: admission 0.97 1.34 0.88 0.44 0.27 0.65 1.91
History discrepancies: discharge 1.41 2.02 1.10 1.47 0.39 0.22 0.68
Reconciliation discrepancies: admission and discharge 1.38 1.16 0.44 1.00 2.61 2.29 2.59
Reconciliation discrepancies: admission 0.75 0.82 0.22 0.58 1.22 0.71 1.91
Reconciliation discrepancies: discharge 0.64 0.35 0.23 0.42 1.39 1.59 0.68
Adjudicated results
Number of potentially harmful discrepancies per patient1: total 0.46 0.26 0.45 0.67 0.70 0.82 0.36
Potentially harmful discrepancies: admission 0.16 0.12 0.17 0.17 0.15 0.29 0.09
Potentially harmful discrepancies: discharge 0.30 0.14 0.28 0.50 0.55 0.53 0.27
Potential severity: admission 0.12 0.10 0.12 0.14 0.13 0.23 0.00
Significant
Serious2 0.04 0.03 0.05 0.03 0.03 0.06 0.09
Potential severity: discharge 0.23 0.13 0.21 0.44 0.40 0.32 0.18
Significant
Serious2 0.07 0.01 0.07 0.06 0.15 0.21 0.09
1 Greater than 50% chance that the medication discrepancy identified had potential to harm patient.
2 There were no life-threatening discrepancies.
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ation interventions [27,35].
Challenges have arisen during the initial implementa-
tion. From a research perspective, these included delays
in signing data use agreements, IRB requirement for pa-
tient consent at some sites, delays in obtaining IRB ap-
proval, and staffing challenges, all of which led to delays
in completing baseline data collection. Another chal-
lenge was achieving adequate response rates from front-
line surveys. In the end, we asked each site to identify a
select group of clinicians likely to complete surveys
while still representative of the locations and provider
types involved in the medication reconciliation process,
sacrificing some generalizability for better rates (and
thus internal validity). Operationally, rather than create
a distinct “version 2” of the intervention, we chose to it-
eratively refine and add to our toolkit as sites and men-
tors have identified specific needs, although we do plan
to develop a distinct “second edition” of the implemen-
tation guide.
To date, initial site visits have been conducted at 3 of
the 6 sites within 4 months of start of the intervention im-
plementation. Feedback after mentor and qualitative re-
searcher visits were shown to be more valuable at sites
that were further along with intervention implementation.This timing allowed for more feedback on barriers and fa-
cilitators to implementation from focus group participants
intimately involved in the intervention, and allowed for
richer data collection on intervention fidelity, creating
more detailed feedback to sites on how to improve their
interventions going forward. On the other hand, because
site visits also enhanced the visibility and institutional sup-
port of the project at the sites, for those sites that were
struggling with implementation, the decision was made to
conduct these visits on time anyway, trading some data
loss regarding intervention fidelity for gains in local
support.
MARQUIS seeks to improve medication safety at
participating hospitals, while rigorously studying the
implementation of a best practices toolkit and con-
textual factors that may influence outcomes. As such,
the study offers one approach to conducting rigorous,
“real world” QI research in which we hope to under-
stand: 1) the most important components of the inter-
vention; 2) reasons for success or failure; and, 3)
barriers and facilitators of implementation. MARQUIS
also attempts to balance the criticism for a more
case-based approach to QI research with more rigor-
ous outcome assessment that adequately adjusts for
potential confounders.
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resources for the intervention and only a small stipend
for data collection, similar to QI efforts at most hospi-
tals. This lowered the cost of the study and also makes it
more generalizable since other sites wishing to adopt the
intervention toolkit most likely would not receive exter-
nal resources for implementation. Nevertheless, this also
makes sites more vulnerable to resource constraints and
changes in leadership or institutional priorities, in par-
ticular during the lag time between applying for funding
and beginning the intervention. As hospitals are increas-
ingly challenged to conserve resources, projects like
MARQUIS are more likely to succeed if medication
safety is a consistent priority or if a favorable return on
investment is anticipated. To address the latter, we have
provided sites with business plans on making the busi-
ness case for medication reconciliation, which is avail-
able online in the MARQUIS implementation guide.
Other challenges reflect the need to balance the needs
of QI work with research, such as the length of pre-
intervention data collection (shorter for QI, longer for
research) and the optimal timing of site visits (earlier for
QI to enlist institutional support, later for research to
best assess intervention fidelity).
Despite these challenges, our use of a mentored im-
plementation model makes MARQUIS a generalizable
approach to studying the improvement of complex pro-
cesses like inpatient medication reconciliation. If the
intervention is shown to be successful, mentored imple-
mentation resources could easily be scaled up. Using a
refined version of the tools and implementation lessons,
MARQUIS holds promise to provide a large impact on
medication safety during transitions in care across many
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